Brilliant Violet 421™ anti-mouse IL-10

Antibodies Single
Sony
JES5-16E3
Flow Cytometry
Rat IgG2b, κ
Mouse
<I>E. coli</I>-expressed, recombinant mouse IL-10
3125105
$203.00

Description

IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. IL-10 inhibits IFN-γ, TNF-β, and IL-2 production by Th1 clones; inhibits macrophage-mediated IL-1, IL-6, and TNF-α synthesis; suppresses the delayed type hypersensitivity response; stimulates Th2 cell response (which results in elevated antibody production); and promotes mast cell proliferation in combination with IL-4.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the microg size, the suggested use of this reagent is ≤0.5 microg per million cells in 100 microL volume. For immunofluorescent staining using the microL size, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Simkin G, et al. 2000. J. Immunol. 164:2457.
2. Kitagaki K, et al. 2002. Clin. Diagn. Lab Immunol. 9:1260.
3. Khanna A, et al. 2000. J. Immunol. 164:1346.
4. Sander B, et al. 1993. J. Immunol. Methods 166:201.
5. Litton M, et al. 1994. J. Immunol. Methods 175:47.
6. Andersson U, et al. 1999. Detection and qunatification of gene expression. New York:Springer-Verlag.
7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
8. Wang W, et al. 2004. FASEB J. 18:1043.
9. Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
10. Lawson BR, et al. 2007. J. Immunol. 178:5366.
11. Xu G, et al. 2007. J. Immunol. 179:5358. PubMed
12. Brummel R, et al. 2005. J. Immunol.174:2429. PubMed
13. Kang YJ, et al. 2007. Stem Cells 25:1814. PubMed
14. Seo N, et al. 2001. Immunology. 103:449. (Neut)